Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Health, Science Ministries Solicit Public Comments on New Clinical Research Ethics Guidelines
August 12, 2014
- Editor’s Pick: Five Healthcare News Headlines for July 28 - August 8
August 11, 2014
- PAFSC Second Committee Supports Approval of G-CSF Drug Pegfilgrastim
August 11, 2014
- Upcoming Act on Pharmaceuticals and Medical Devices to Require “Latest Information in Package Inserts”: PFSB
August 11, 2014
- MHLW Orders Revision of Package Insert for Remicade
August 8, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 3: Dr Yamamoto of SCJ
August 8, 2014
- Govt to Enhance Support to Boost Pharma Sector’s Competitiveness: Health Policy Bureau Head
August 7, 2014
- Health Insurance Bureau Chief Says Discussions on Accurate Market Prices and Frequency of NHI Price Revisions Important
August 7, 2014
- MHLW Issues Notification Calling for Compliance with GVP Ministerial Ordinance
August 7, 2014
- MHLW to Survey Rate of Generic Drug Use Under High-Cost Healthcare System; Regulatory Reform Council Concerned that System Provides Little Incentive to Use Generics
August 6, 2014
- PFSB’s Budget Request for FY2015 Will Seek Funding to Strengthen Operations at PMDA: Director-General
August 6, 2014
- MHLW to Remind Drug Makers of Proper ADR Reporting in Wake of Administrative Improvement Order to Novartis
August 4, 2014
- MHLW to Fund Research Aimed at Obtaining Additional Indications for Intractable and Orphan Diseases for Existing Drugs
August 4, 2014
- PAFSC First Committee Backs Approval of MSD’s Insomnia Treatment
August 4, 2014
- JPMA to Examine Clinical Trial Costs
August 1, 2014
- Improvement Order Issued to Novartis over Delayed ADR Reporting
August 1, 2014
- Government to Increase Review Fee for New Generic Drugs from 630,000 Yen to 940,000 Yen
August 1, 2014
- JPA’s Abe Makes Chuikyo Debut, Says No to Annual Drug Price Revisions
July 31, 2014
- Regulatory Review Trend in Japan Signals Pharmas’ Shift to Cancer Drugs: Jiho Tally
July 30, 2014
- MHLW Bulletin Notifies of Revised Package Inserts Warning Concurrent Use of ARBs, ACE Inhibitors
July 30, 2014
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…